Protective Effects of the Chinese Prescription Hachimi-jio-gan Against Diabetic Oxidative Stress
Overview
Pharmacy
Affiliations
We used rats with streptozotocin (STZ)-induced diabetes to investigate the effects of Hachimi-jiogan on diabetic oxidative stress. Oral administration of Hachimi-jio-gan, at a dose of 50, 100 or 200 mg kg(-1) (body weight) daily, for 10 days to rats with STZ-induced diabetes resulted in significant dose-dependent decreases in serum levels of glucose and glycosylated protein, implying that Hachimi-jio-gan improves the abnormal glucose metabolism that leads to oxidative stress. Hachimi-jio-gan also showed a tendency to reduce the urine volume and significantly reduced the elevated urinary protein level. Moreover, rats with STZ-induced diabetes had high serum levels of superoxide and nitrite/nitrate. However, the administration of Hachimi-jio-gan dose-dependently reduced the overproduction of radicals associated with diabetes, suggesting the role of Hachimijio-gan as a radical scavenger that could protect against diabetic oxidative stress. Furthermore, thiobarbituric acid-reactive substance levels in serum and hepatic and renal mitochondria were dose-dependently lower in the Hachimi-jio-gan-treated groups than in the control diabetic group, which implies that Hachimi-jio-gan would alleviate the oxidative stress associated with diabetes through the inhibition of lipid peroxidation. These results indicate that Hachimi-jio-gan is a potential therapeutic agent that will reduce the damage caused by oxidative stress involved in diabetes.
Yagi H, Nishio K, Sato R, Arai G, Soh S, Okada H J Tradit Complement Med. 2016; 6(1):126-9.
PMID: 26870690 PMC: 4737965. DOI: 10.1016/j.jtcme.2014.11.021.
Lee A, Chen B, Mou C, Sun M, Yen H Medicine (Baltimore). 2016; 95(3):e2536.
PMID: 26817897 PMC: 4998271. DOI: 10.1097/MD.0000000000002536.
Watanabe K, Shimada A, Miyaki K, Hirakata A, Matsuoka K, Omae K Evid Based Complement Alternat Med. 2014; 2014:128726.
PMID: 24812564 PMC: 4000675. DOI: 10.1155/2014/128726.
Chaiyasut C, Kusirisin W, Lailerd N, Lerttrakarnnon P, Suttajit M, Srichairatanakool S Evid Based Complement Alternat Med. 2011; 2011:749307.
PMID: 21423638 PMC: 3057567. DOI: 10.1155/2011/749307.